Source: Virtual Congress 2021 – Clinical problems associated with cough, pleura and respiratory health status



Rating:

Share or cite this content

Citations should be made in the following way:
C. Nwagboso (Calabar, Nigeria), B. Ekeng (Calabar, Nigeria), E. Ochang (Calabar, Nigeria), J. Eze (Calabar, Nigeria), C. Echieh (Calabar, Nigeria), S. Ogbudu (Calabar, Nigeria), A. Etiuma (Calabar, Nigeria), O. Bassey (Calabar, Nigeria). Analysis of the microbial profile and antimicrobial resistant pattern of empyema thoracis. 3126

Member's Comments

No comment yet.

Related content which might interest you: Clinicoradiological profile and treatment outcome of empyema thoracis patients Source: Virtual Congress 2021 – Bronchiectasis and pleural infection Year: 2021 Identification of microbiome etiology associated with drug resistance in pleural empyema Source: Virtual Congress 2021 – Bronchiectasis and pleural infection Year: 2021 Role of Abram‘s pleural biopsy in determining the cause of empyema thoracis Source: Annual Congress 2012 - Medical access to the pleura Year: 2012 The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006 Immunomodulatory properties of macrolide antibiotics in the treatment of bronchial sepsis involving P. aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 639s Year: 2004 Empyema thoracis: therapeutic management and outcome Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Antimicrobial susceptibility of atypical pathogens Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Evolution of antimicrobial resistance trends in the last five years in patients with bacteremic Pneumococcal community-acquired pneumonia (CAP-SP) Source: Eur Respir J 2005; 26: Suppl. 49, 639s Year: 2005 Antimicrobial peptides and airway bacterial colonization in bronchiectasis Source: International Congress 2018 – Bronchiectasis: phenotypes, endotypes and new therapies Year: 2018 Current management of empyema thoracis in childhood Source: Eur Respir J 2002; 20: Suppl. 38, 590s Year: 2002 Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2014; 43: 884-897 Year: 2014 Cytokine profile in patients with widespread MDR tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 504s Year: 2006 Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009 Analysis of antibiotic resistance and enterococcal infections of low respiratory infection on patients in hospital Source: Eur Respir J 2003; 22: Suppl. 45, 450s Year: 2003 Antibiotic usage analysis of the community-acquired pneumonia at young patients from different social groups Source: Eur Respir J 2003; 22: Suppl. 45, 149s Year: 2003 Potential antibiotic resistant pathogens in community-acquired pneumonia: playing it safe is anything but Source: Eur Respir J, 54 (1) 1900870; 10.1183/13993003.00870-2019 Year: 2019 Comparative clinical analysis of COVID-19 pneumonia and bacterial pneumonia Source: Virtual Congress 2021 – Acute paediatric respiratory infections Year: 2021 Treatment of empyema thoracis by medical thoracoscopy Source: Eur Respir J 2002; 20: Suppl. 38, 71s Year: 2002 Effect of fluoroquinolones on microbiologic outcome and survival in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 380s Year: 2006